Acute myeloid leukemia (AML) Clinical Trials

Recruiting acute myeloid leukemia (aml) studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat acute myeloid leukemia (aml). Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting acute myeloid leukemia (aml) studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting acute myeloid leukemia (aml) trials

Within

Universal 4SCAR7U Targeting CD7-positive Malignancies

for T-cell Acute Lymphoblastic Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 6 Months - 75

Code: NCT05995028·Phase 1

Universal CAR-T Cells Targeting AML

for Acute Myeloid Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 6 Months - 75

Code: NCT05995041·Phase 1

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

25 sites incl. Bloomington

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 60+

Code: NCT07437950·Phase 2

Apply to this trial

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia With Complex Karyotype

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07582172·Phase 2

Apply to this trial

GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors

for Acute Myeloid Leukemia

Sponsor: Vitruviae

Sex: All·Age: 6 Months+

Code: NCT07749976·Phase 1, Phase 2

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

for Acute Myeloid Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 2 - 75

Code: NCT03222674·Phase 1, Phase 2

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

for T-cell Acute Lymphoblastic Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 6 Months - 75

Code: NCT04033302·Phase 1, Phase 2

Menin-Inhibitor Targeted Maintenance in AML

for Relapsed Adult AML

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: 18+

Code: NCT07563010·Phase 2

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

for Recurrent Acute Myeloid Leukemia

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07583303·Phase 1

Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

for Hematologic Malignancy

Sponsor: Ossium Health, Inc.

Sex: All·Age: 12 - 75

Code: NCT07710781

Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia

for Acute Myeloid Leukemia

1 site in Rochester

Sponsor: University of Rochester

Sex: All·Age: 60+

Code: NCT07735208·Phase 2

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

for Acute Myeloid Leukemia

1 site in Ann Arbor

Sponsor: University of Michigan Rogel Cancer Center

Sex: All·Age: 21+

Code: NCT07737769·Phase 1

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

for Acute Lymphoid Leukemia

1 site in Tucson

Sponsor: University of Arizona

Sex: All·Age: Up to 65

Code: NCT07254793·Phase 1

Allogeneic iNKT Cell Therapy (agenT-797) After SCT

for Allogenic Stem Cell Transplantation

1 site in Madison

Sponsor: University of Wisconsin, Madison

Sex: All·Age: 18+

Code: NCT07758218·Phase 1

A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia

for Relapsed Acute Myeloid Leukemia

Sponsor: BeOne Medicines

Sex: All·Age: 6 Months - 17

Code: NCT07770698·Phase 1, Phase 2

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

for Acute Myeloid Leukemia

Sponsor: Institut Paoli-Calmettes

Sex: All·Age: 18 - 75

Code: NCT07598110·Phase 2

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

for Acute Myeloid Leukemia

1 site in Columbus

Sponsor: Uma Borate

Sex: All·Age: 18+

Code: NCT06930352·Phase 2

Apply to this trial

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

for Acute Myeloid Leukemia

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07549464·Phase 1

A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

for Acute Myeloid Leukemia

1 site in Seattle

Sponsor: University of Washington

Sex: All·Age: 18+

Code: NCT07616921

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

for Acute Myeloid Leukemia

Sponsor: French Innovative Leukemia Organisation

Sex: All·Age: 55+

Code: NCT07463768·Phase 2

A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

for Acute Myeloid Leukemia

Sponsor: Servier

Sex: All·Age: 18+

Code: NCT07719348·Phase 1, Phase 2

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

for Acute Leukemia of Ambiguous Lineage

1 site in Seattle

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18+

Code: NCT07094750

Apply to this trial

Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)

for Myeldysplastic Syndrome (MDS)

Sponsor: University of Manitoba

Sex: All·Age: 18+

Code: NCT07528417·Phase 2

FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

for Acute Myeloid Leukemia

1 site in Seattle

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18+

Code: NCT07645469·Phase 1

Apply to this trial

Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality

for Acute Myeloid Leukemia

Sponsor: IRCCS San Raffaele

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07743047

Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia

for Acute Myeloid Leukemia

Sponsor: Florian Kuchenbauer

Sex: All·Age: 18+

Code: NCT07755202·Phase 2

Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)

for Myelodysplastic Syndromes

Sponsor: University of Utah

Sex: All·Age: 18+

Code: NCT07570056

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

for Acute Myeloid Leukemia

1 site in St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT07617363·Phase 1

Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

for Acute Myeloid Leukemia

1 site in Palo Alto

Sponsor: Stanford University

Sex: All·Age: 18 - 70

Code: NCT07634536·Phase 2

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

for Sarcoma

1 site in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 15 - 24

Code: NCT07516353

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

for Acute Myeloid Leukemia

1 site in Atlanta

Sponsor: Northside Hospital, Inc.

Sex: All·Age: 18+

Code: NCT07511062·Phase 1

Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation

for Allogeneic HSCT

Sponsor: University Hospital Pilsen

Sex: All·Age: 18 - 70

Code: NCT07570407

Apply to this trial

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

for Myeloid Disorders

1 site in Milwaukee

Sponsor: Medical College of Wisconsin

Sex: All·Age: 18+

Code: NCT07572929·Phase 2

Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients

for Bone Marrow Transplantation

Sponsor: Yasmin medhat munir Mohamed

Sex: All·Age: 2 - 65

Code: NCT07695571

HMA-Venetoclax Induction in Newly Diagnosed AML

for AML

Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group

Sex: All·Age: 18 - 50

Code: NCT07748455·Phase 2

Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions

for Acute Myeloid Leukemia

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Sex: All·Age: 18+

Code: NCT07080970

Apply to this trial

Motixafortide for MRD Sensitization in AML

for Acute Myeloid Leukemia

1 site in St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT07392970·Phase 2

Apply to this trial

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 75

Code: NCT06954987·Phase 2

Plasma ctDNA Monitoring in Pediatric Acute Leukemia

for Acute Myeloid Leukemia

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Sex: All·Age: 3 - 18

Code: NCT07751588

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554419·Phase 2

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

for Acute Myeloid Leukemia

Sponsor: Shen yang

Sex: All·Age: 18 - 65

Code: NCT07664839·Phase 2

SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS

for Acute Myeloid Leukemia

Sponsor: The First Affiliated Hospital of Soochow University

Sex: All·Age: 15 - 60

Code: NCT07562568·Phase 2

TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission

for Acute Myeloid Leukemia

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Sex: All·Age: 55 - 75

Code: NCT07563920

SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS

for Acute Myeloid Leukemia

Sponsor: The First Affiliated Hospital of Soochow University

Sex: All·Age: 18 - 65

Code: NCT07575412·Phase 2

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

for Acute Myeloid Leukemia

3 sites incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07581002·Phase 2, Phase 3

Apply to this trial

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

for AML

26 sites incl. Gilbert

Sponsor: TScan Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07702578·Phase 3

Apply to this trial

A Study of CRD3874-SI in People With Leukemia

for Acute Myeloid Leukemia

7 sites incl. Basking Ridge

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT07661095·Phase 1

Apply to this trial

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

for Acute Myeloid Leukemia

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18 - 75

Code: NCT06996119·Phase 1

Apply to this trial

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

for Acute Myeloid Leukemia Post Cytotoxic Therapy

11 sites incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 21

Code: NCT07012044·Phase 1

Apply to this trial

Phase I Study of FXS0683 in the Treatment of Blood Tumors

for B-Cell Lymphoma

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Sex: All·Age: 18+

Code: NCT07616089·Phase 1

VA Consolidation in Intermediate-Risk AML

for Acute Myeloid Leukemia

Sponsor: The First Affiliated Hospital of Soochow University

Sex: All·Age: 18+

Code: NCT07672262·Phase 2

Apply to this trial

Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

for Acute Myeloid Leukemia

Sponsor: University of Freiburg

Sex: All·Age: 18+

Code: NCT07627568

Apply to this trial

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

for Acute Myeloid Leukemia

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07153497·Phase 2

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

for Acute Myeloid Leukemia

36 sites incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 1 - 25

Code: NCT07022678·Phase 3

Apply to this trial

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

for AML

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07508982·Phase 1, Phase 2

Apply to this trial

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

for Acute Myeloid Leukemia

4 sites incl. Palo Alto

Sponsor: AbbVie

Sex: All·Age: 6 Months - 17

Code: NCT07306832·Phase 1

Apply to this trial

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

for Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

3 sites incl. Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18 - 75·Accepts healthy volunteers

Code: NCT07020533·Phase 1

Apply to this trial

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

for AML

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Sex: All·Age: 14 - 100

Code: NCT07490288

Apply to this trial

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

for AML

Sponsor: Peking University People's Hospital

Sex: All·Age: 18 - 70

Code: NCT07617285·Phase 1

Apply to this trial

Study of SA+X in the Treatment of Newly Diagnosed AML

for Acute Myeloid Leukemia

Sponsor: Ruijin Hospital

Sex: All·Age: 18+

Code: NCT07548710·Phase 2

Apply to this trial

New trials in Duarte, CA?

Pick a condition and we'll email you once a week when a new study starts recruiting in Duarte, CA. Unsubscribe anytime.

Acute myeloid leukemia (AML) clinical trials — common questions

Are acute myeloid leukemia (aml) clinical trials free to join?

Yes. Participating in a acute myeloid leukemia (aml) clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a acute myeloid leukemia (aml) clinical trial?

Each acute myeloid leukemia (aml) study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a acute myeloid leukemia (aml) trial near me?

Use the location controls above. We'll show recruiting acute myeloid leukemia (aml) trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many acute myeloid leukemia (aml) trials are recruiting right now?

We're currently tracking roughly 264 recruiting acute myeloid leukemia (aml) trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Acute myeloid leukemia (AML) trials by city

Duarte, CA Seattle, WA Birmingham, AL Boston, MA Miami, FL Portland, OR Tampa, FL Aurora, CO Los Angeles, CA Palo Alto, CA Sacramento, CA Cleveland, OH

Related specialties

Oncology Blood cancer